Alzheimer's disease: new approaches to drug discovery

In this work, we review and comment upon the challenges and the ‘quo vadis’ in Alzheimer's disease drug discovery at the beginning of the new millennium. We emphasize recent approaches that, moving on from a target-centric approach, have produced innovative molecular probes or drug candidates....

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in chemical biology 2009-06, Vol.13 (3), p.303-308
Main Authors: Bolognesi, Maria L, Matera, Riccardo, Minarini, Anna, Rosini, Michela, Melchiorre, Carlo
Format: Article
Language:English
Subjects:
Alzheimer Disease - drug therapy
Amyloid Precursor Protein Secretases - antagonists & inhibitors
Aspartic Acid Endopeptidases - antagonists & inhibitors
Drug Delivery Systems - methods
Drug Discovery - methods
Humans
Indans - chemistry
Organophosphorus Compounds - chemistry
Ubiquinone - analogs & derivatives
Ubiquinone - chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this work, we review and comment upon the challenges and the ‘quo vadis’ in Alzheimer's disease drug discovery at the beginning of the new millennium. We emphasize recent approaches that, moving on from a target-centric approach, have produced innovative molecular probes or drug candidates. In particular, the discovery of endosome-targeted BACE1 inhibitors and mitochondria-targeted antioxidants represents a significant advance in Alzheimer's research and therapy. The case study of the development of rasagiline provides an excellent example to support the validity of the multitarget-designed ligand approach to the search for effective medicines for combating Alzheimer's disease.
ISSN:1367-5931
1879-0402
DOI:10.1016/j.cbpa.2009.04.619